...
首页> 外文期刊>Regulatory Toxicology and Pharmacology: RTP >Reference dose for perchlorate based on thyroid hormone change in pregnant women as the critical effect.
【24h】

Reference dose for perchlorate based on thyroid hormone change in pregnant women as the critical effect.

机译:高氯酸盐参考剂量以孕妇甲状腺激素的变化为关键作用。

获取原文
获取原文并翻译 | 示例
           

摘要

The most relevant data for developing a reference dose (RfD) for perchlorate exposures comes from human epidemiology and clinical studies, supplemented with available and extensive information on experimental animals. Specifically, serum T4 decrease is the critical effect of perchlorate, based on a mode-of-action analysis and the evidence provided by the body of rodent studies on perchlorate. However, no T4 decreases have been observed in human populations following perchlorate exposure at non-therapeutic doses. An RfD of 0.002 mg/kg-day can be derived using an epidemiology study. A freestanding NOAEL of 0.006 mg/kg-day for T4 decrease was identified in children from the epidemiology study. The use of this NOAEL has the advantage of a being identified in a sensitive subgroup, neonates and children. Data are sufficient to estimate an overall uncertainty factor of 3-fold with this NOAEL based on expected differences in toxicokinetics and toxicodynamics between children, and pregnant women and their fetuses, the second identified sensitive subgroup for perchlorate, and concerns about the over-iodination of this population. This RfD is supported by a human clinical study using inhibition of iodine uptake in adults as a measurable surrogate for the critical effect of T4 decrease in humans. However, although this latter study has a well-established dose-response curve for inhibition of iodine uptake, even perchlorate doses that result in a 70% inhibition of iodine uptake have no apparent effect on human T4 levels. Thus, the use of this study as the primary basis of the RfD is problematic. Nevertheless, a benchmark dose of 0.01 mg/kg-day was identified in this clinical study, which supports a threshold value of 0.006 mg/kg-day identified by its authors and the RfD of 0.002 mg/kg-day estimated in this paper.
机译:制定高氯酸盐暴露参考剂量(RfD)的最相关数据来自人类流行病学和临床研究,并补充了有关实验动物的大量可用信息。具体来说,根据作用方式分析和啮齿动物研究机构提供的证据,血清T4的降低是高氯酸盐的关键作用。但是,在非治疗剂量的高氯酸盐接触后,在人群中未观察到T4降低。使用流行病学研究可以得出RfD为0.002 mg / kg-day。根据流行病学研究,儿童中T4减少的独立NOAEL为0.006 mg / kg-day。使用该NOAEL的优势是可以在敏感亚组,新生儿和儿童中被识别。数据足以根据儿童,孕妇及其胎儿,第二个确定的高氯酸盐敏感亚组之间的毒物代谢动力学和毒理动力学差异预期,估计该NOAEL的总体不确定性因子为3倍,并担心碘的过量碘化这个人口。该RfD得到了一项人类临床研究的支持,该研究使用了抑制成年人摄取碘的手段,以此作为衡量人类T4降低的关键作用的替​​代指标。然而,尽管后一项研究具有完善的抑制碘摄取的剂量反应曲线,但即使导致高碘酸盐抑制70%的高氯酸盐剂量也对人T4水平没有明显影响。因此,将这项研究用作RfD的主要基础是有问题的。然而,在这项临床研究中确定了0.01 mg / kg-day的基准剂量,这支持了作者确定的0.006 mg / kg-day的阈值和本文估计的0.002 mg / kg-day的RfD。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号